The accumulation of misfolded proteins represents a common pathological mechanism of most major neurodegenerative disorders. Neuronal inclusions comprised of aggregated a-Synuclein (aSyn) are known as Lewy bodies (LBs) and Lewy-neurites (LNs), and represent a key histopathological feature of Parkinson's disease (PD), and a family of related disorders known as synucleinopathies that affect as many as 1 million individuals in the U.S. alone. Mutations in the SNCA gene encoding aSyn also cause familial PD but while histological and genetic evidence firmly indicate a correlation between aSyn accumulation and disease, how aSyn pathology forms and whether it directly contributes to disease remains unclear. Abnormal aSyn catalyzes the misfolding of the normal protein and it has recently been demonstrated that minute quantities of aSyn aggregates can trigger the formation of toxic LBs/LNs in cultured neurons. Misfolded aSyn also induces the formation of LBs/LNs in healthy non-transgenic mice. In both human PD and animal models, aSyn pathology progressively propagates and spreads to neuroanatomically connected regions, reminiscent of prion diseases. Importantly, animals with LBs/LNs recapitulate the cardinal features of PD, including progressive loss of dopamine-producing neurons and locomotor deficits. This proposed research plan addresses key biological questions posed by these findings, and combines novel in vitro, cell-based, and in vivo tools to further understand how LBs/LNs are form, propagate, and ultimately contribute to neurodegeneration and neurological symptoms.
Aim 1 examines whether neurons in multiple brain regions develop LBs/LNs following inoculation with misfolded recombinant aSyn and subsequently undergo cell death. A recently developed tissue processing method will be used to determine if LBs/LNs spread via neuronal projections, as hypothesized for human PD, or by other mechanisms. Behavioral tests will then reveal if specific clinicopathological correlations exist.
Aim 2 will define the molecular interactions that govern how abnormal aSyn triggers the conversion of normal aSyn in LBs/LNs, by testing the ability of mutant aSyn sequences to seed pathology in both cells and in vivo following stereotactic injection. Finally, Aim 3 will elucidate the cellular and molecular mechanisms by which aSyn induce intracellular pathology by using cell-based, in vivo, and proteomics approaches to compare LB/LN-inducing and non-inducing aSyn mutants that we have recently discovered. Completion of these studies should provide valuable insights into the potential mechanisms by which aSyn contribute to the progression of PD. Increased understanding of the pathogenesis of this and related synucleinopathies should ultimately result in disease-modifying therapies for this group of incurable disorders.

Public Health Relevance

The brains of individuals with Parkinson's disease gradually develop abnormal protein deposits called Lewy bodies but it is not known how they contribute to disease. This study uses a recently discovered method that causes brain cells to form these lesions, allowing the investigation of how they impair the function and survival of neurons. Better understanding of these processes could lead to the development of new therapies for Parkinson's disease and other neurodegenerative disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS088322-04
Application #
9451342
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Sutherland, Margaret L
Project Start
2015-03-13
Project End
2020-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Luna, Esteban; Decker, Samantha C; Riddle, Dawn M et al. (2018) Differential ?-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathol 135:855-875
Akhtar, Rizwan S; Licata, Joseph P; Luk, Kelvin C et al. (2018) Measurements of auto-antibodies to ?-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. J Neurochem 145:489-503
Manfredsson, Fredric P; Luk, Kelvin C; Benskey, Matthew J et al. (2018) Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis 112:106-118
Duffy, Megan F; Collier, Timothy J; Patterson, Joseph R et al. (2018) Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation 15:129
Ugras, Scott; Daniels, Malcolm J; Fazelinia, Hossein et al. (2018) Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in ?-Synuclein Aggregation Disorders. EBioMedicine 31:307-319
Polinski, Nicole K; Volpicelli-Daley, Laura A; Sortwell, Caryl E et al. (2018) Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. J Parkinsons Dis 8:303-322
Nouraei, Negin; Mason, Daniel M; Miner, Kristin M et al. (2018) Critical appraisal of pathology transmission in the ?-synuclein fibril model of Lewy body disorders. Exp Neurol 299:172-196
Luk, Kelvin C; Covell, Dustin J; Kehm, Victoria M et al. (2016) Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. Cell Rep 16:3373-3387
Mason, Daniel M; Nouraei, Negin; Pant, Deepti B et al. (2016) Transmission of ?-synucleinopathy from olfactory structures deep into the temporal lobe. Mol Neurodegener 11:49
Luna, Esteban; Luk, Kelvin C (2015) Bent out of shape: ?-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS Lett 589:3749-59